氟尿嘧啶植入剂的研究进展及其在腺癌中的临床应用  

Advances in study of fluorouracil for implantation and its clinical application in adenocarcinoma

作　　者：昝培霞[1] 颜士杰[2] 

机构地区：[1]安徽医科大学 [2]安徽医科大学第一附属医院妇产科

出　　处：《中国临床药理学与治疗学》2010年第7期827-831,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：氟尿嘧啶植入剂是一种新型的植入用缓释氟尿嘧啶制剂,是国家食品药品监督管理局批准的第一个抗肿瘤控释植入剂。氟尿嘧啶植入剂的主要有效成分为5-氟尿嘧啶。氟尿嘧啶植入剂可提高局部药物浓度,延长有效药物浓度时间,降低全身毒副反用。本文综述了氟尿嘧啶植入剂的药代动力学、药理作用及在腺癌中的临床应用。Fluorouracil for implantation is a new implanting sustained release preparation, and it is the first tumor therapy controlled release implantation that has been ratified by SFDA.5-fluorouracil is the main component of fluorouracil for implantation. Fluorouracil for implantation can elevate the local drug concentration,extend the time of effective drug concentration,reduce the general toxic and side-effect. The article contains fluorouracil for implantation pharmacokinetics, pharmacologic and apply to adenocarcinoma.

关 键 词：氟尿嘧啶植入剂 腺癌 临床应用 

分 类 号：R969[医药卫生—药理学]